-
1
-
-
7844225540
-
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
-
Berinstein N.L., Grillo-Lopez A.J., White C.A., Bence-Bruckler I., Maloney D., Czuczman M., Green D., Rosenberg J., McLaughlin P., Shen D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 1998, 9:995-1001.
-
(1998)
Ann. Oncol.
, vol.9
, pp. 995-1001
-
-
Berinstein, N.L.1
Grillo-Lopez, A.J.2
White, C.A.3
Bence-Bruckler, I.4
Maloney, D.5
Czuczman, M.6
Green, D.7
Rosenberg, J.8
McLaughlin, P.9
Shen, D.10
-
2
-
-
3142564395
-
Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas
-
Beum P.V., Kennedy A.D., Taylor R.P. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Meth. 2004, 289:97-109.
-
(2004)
J. Immunol. Meth.
, vol.289
, pp. 97-109
-
-
Beum, P.V.1
Kennedy, A.D.2
Taylor, R.P.3
-
3
-
-
34547850227
-
Evaluation of a peptide ELISA for the detection of rituximab in serum
-
Blasco H., Lalmanach G., Godat E., Maurel M.C., Canepa S., Belghazi M., Paintaud G., Degenne D., Chatelut E., Cartron G., Le Guellec C. Evaluation of a peptide ELISA for the detection of rituximab in serum. J. Immunol. Meth. 2007, 325:127-139.
-
(2007)
J. Immunol. Meth.
, vol.325
, pp. 127-139
-
-
Blasco, H.1
Lalmanach, G.2
Godat, E.3
Maurel, M.C.4
Canepa, S.5
Belghazi, M.6
Paintaud, G.7
Degenne, D.8
Chatelut, E.9
Cartron, G.10
Le Guellec, C.11
-
4
-
-
4944220440
-
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
-
Cragg M.S., Bayne M.B., Tutt A.L., French R.R., Beers S., Glennie M.J., Illidge T.M. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 2004, 104:2540-2542.
-
(2004)
Blood
, vol.104
, pp. 2540-2542
-
-
Cragg, M.S.1
Bayne, M.B.2
Tutt, A.L.3
French, R.R.4
Beers, S.5
Glennie, M.J.6
Illidge, T.M.7
-
5
-
-
39449114054
-
Biomarker method validation in anticancer drug development
-
Cummings J., Ward T.H., Greystoke A., Ranson M., Dive C. Biomarker method validation in anticancer drug development. Br. J. Pharmacol. 2008, 153:646-656.
-
(2008)
Br. J. Pharmacol.
, vol.153
, pp. 646-656
-
-
Cummings, J.1
Ward, T.H.2
Greystoke, A.3
Ranson, M.4
Dive, C.5
-
6
-
-
0033067232
-
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab
-
Davis T.A., White C.A., Grillo-Lopez A.J., Velasquez W.S., Link B., Maloney D.G., Dillman R.O., Williams M.E., Mohrbacher A., Weaver R., Dowden S., Levy R. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J. Clin. Oncol. 1999, 17:1851-1857.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 1851-1857
-
-
Davis, T.A.1
White, C.A.2
Grillo-Lopez, A.J.3
Velasquez, W.S.4
Link, B.5
Maloney, D.G.6
Dillman, R.O.7
Williams, M.E.8
Mohrbacher, A.9
Weaver, R.10
Dowden, S.11
Levy, R.12
-
7
-
-
10744230729
-
Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules
-
DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 2003, 20:1885-1900.
-
(2003)
Pharm. Res.
, vol.20
, pp. 1885-1900
-
-
DeSilva, B.1
Smith, W.2
Weiner, R.3
Kelley, M.4
Smolec, J.5
Lee, B.6
Khan, M.7
Tacey, R.8
Hill, H.9
Celniker, A.10
-
8
-
-
0033989957
-
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective
-
Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 2000, 21:1249-1273.
-
(2000)
J. Pharm. Biomed. Anal.
, vol.21
, pp. 1249-1273
-
-
Findlay, J.W.1
Smith, W.C.2
Lee, J.W.3
Nordblom, G.D.4
Das, I.5
DeSilva, B.S.6
Khan, M.N.7
Bowsher, R.R.8
-
9
-
-
0003177157
-
Directive 2001/20/EC of the European Parliament and of the Council: on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practise in the conduct of clinical trials on medicinal products for human use
-
Fontaine N., Rosengren B. Directive 2001/20/EC of the European Parliament and of the Council: on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practise in the conduct of clinical trials on medicinal products for human use. OJEC 2001, 34-44.
-
(2001)
OJEC
, pp. 34-44
-
-
Fontaine, N.1
Rosengren, B.2
-
10
-
-
0036177103
-
Rituximab: ongoing and future clinical development
-
Grillo-Lopez A.J., Hedrick E., Rashford M., Benyunes M. Rituximab: ongoing and future clinical development. Semin. Oncol. 2002, 29(Suppl 2):105-112.
-
(2002)
Semin. Oncol.
, vol.29
, Issue.SUPPL 2
, pp. 105-112
-
-
Grillo-Lopez, A.J.1
Hedrick, E.2
Rashford, M.3
Benyunes, M.4
-
11
-
-
58149464696
-
A review of the current use of rituximab in autoimmune diseases
-
Gurcan H.M., Keskin D.B., Stern J.N., Nitzberg M.A., Shekhani H., Ahmed A.R. A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol. 2009, 9:10-25.
-
(2009)
Int. Immunopharmacol.
, vol.9
, pp. 10-25
-
-
Gurcan, H.M.1
Keskin, D.B.2
Stern, J.N.3
Nitzberg, M.A.4
Shekhani, H.5
Ahmed, A.R.6
-
14
-
-
10344237546
-
Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20
-
Hong K., Presta L.G., Lu Y., Penn A., Adams C., Chuntharapai A., Yang J., Wong W.L., Meng Y.G. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J. Immunol. Meth. 2004, 294:189-197.
-
(2004)
J. Immunol. Meth.
, vol.294
, pp. 189-197
-
-
Hong, K.1
Presta, L.G.2
Lu, Y.3
Penn, A.4
Adams, C.5
Chuntharapai, A.6
Yang, J.7
Wong, W.L.8
Meng, Y.G.9
-
15
-
-
0034090042
-
Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study
-
Iacona I., Lazzarino M., Avanzini M.A., Rupolo M., Arcaini L., Astori C., Lunghi F., Orlandi E., Morra E., Zagonel V., Regazzi M.B. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther. Drug Monit. 2000, 22:295-301.
-
(2000)
Ther. Drug Monit.
, vol.22
, pp. 295-301
-
-
Iacona, I.1
Lazzarino, M.2
Avanzini, M.A.3
Rupolo, M.4
Arcaini, L.5
Astori, C.6
Lunghi, F.7
Orlandi, E.8
Morra, E.9
Zagonel, V.10
Regazzi, M.B.11
-
16
-
-
61849136656
-
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
-
Illidge T.M., Bayne M., Brown N.S., Chilton S., Cragg M.S., Glennie M.J., Du Y., Lewington V., Smart J., Thom J., Zivanovic M., Johnson P.W. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009, 113:1412-1421.
-
(2009)
Blood
, vol.113
, pp. 1412-1421
-
-
Illidge, T.M.1
Bayne, M.2
Brown, N.S.3
Chilton, S.4
Cragg, M.S.5
Glennie, M.J.6
Du, Y.7
Lewington, V.8
Smart, J.9
Thom, J.10
Zivanovic, M.11
Johnson, P.W.12
-
17
-
-
32544451155
-
Fit-for-purpose method development and validation for successful biomarker measurement
-
Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., Rogers J.A., Millham R., O'Brien P.J., Sailstad J., Khan M., Ray C., Wagner J.A. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23:312-328.
-
(2006)
Pharm. Res.
, vol.23
, pp. 312-328
-
-
Lee, J.W.1
Devanarayan, V.2
Barrett, Y.C.3
Weiner, R.4
Allinson, J.5
Fountain, S.6
Keller, S.7
Weinryb, I.8
Green, M.9
Duan, L.10
Rogers, J.A.11
Millham, R.12
O'Brien, P.J.13
Sailstad, J.14
Khan, M.15
Ray, C.16
Wagner, J.A.17
-
18
-
-
20944433395
-
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report
-
Lee J.W., Weiner R.S., Sailstad J.M., Bowsher R.R., Knuth D.W., O'Brien P.J., Fourcroy J.L., Dixit R., Pandite L., Pietrusko R.G., Soares H.D., Quarmby V., Vesterqvist O.L., Potter D.M., Witliff J.L., Fritche H.A., O'Leary T., Perlee L., Kadam S., Wagner J.A. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res. 2005, 22:499-511.
-
(2005)
Pharm. Res.
, vol.22
, pp. 499-511
-
-
Lee, J.W.1
Weiner, R.S.2
Sailstad, J.M.3
Bowsher, R.R.4
Knuth, D.W.5
O'Brien, P.J.6
Fourcroy, J.L.7
Dixit, R.8
Pandite, L.9
Pietrusko, R.G.10
Soares, H.D.11
Quarmby, V.12
Vesterqvist, O.L.13
Potter, D.M.14
Witliff, J.L.15
Fritche, H.A.16
O'Leary, T.17
Perlee, L.18
Kadam, S.19
Wagner, J.A.20
more..
-
19
-
-
17144455839
-
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
-
Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., White C.A., Liles T.M., Royston I., Varns C., Rosenberg J., Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 1997, 15:3266-3274.
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 3266-3274
-
-
Maloney, D.G.1
Grillo-Lopez, A.J.2
Bodkin, D.J.3
White, C.A.4
Liles, T.M.5
Royston, I.6
Varns, C.7
Rosenberg, J.8
Levy, R.9
-
20
-
-
1842368507
-
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
-
Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., Janakiraman N., Foon K.A., Liles T.M., Dallaire B.K., Wey K., Royston I., Davis T., Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
-
(1997)
Blood
, vol.90
, pp. 2188-2195
-
-
Maloney, D.G.1
Grillo-Lopez, A.J.2
White, C.A.3
Bodkin, D.4
Schilder, R.J.5
Neidhart, J.A.6
Janakiraman, N.7
Foon, K.A.8
Liles, T.M.9
Dallaire, B.K.10
Wey, K.11
Royston, I.12
Davis, T.13
Levy, R.14
-
22
-
-
0345337254
-
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
-
McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., Heyman M.R., Bence-Bruckler I., White C.A., Cabanillas F., Jain V., Ho A.D., Lister J., Wey K., Shen D., Dallaire B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998, 16:2825-2833.
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 2825-2833
-
-
McLaughlin, P.1
Grillo-Lopez, A.J.2
Link, B.K.3
Levy, R.4
Czuczman, M.S.5
Williams, M.E.6
Heyman, M.R.7
Bence-Bruckler, I.8
White, C.A.9
Cabanillas, F.10
Jain, V.11
Ho, A.D.12
Lister, J.13
Wey, K.14
Shen, D.15
Dallaire, B.K.16
-
23
-
-
0034852176
-
Workshop on bioanalytical methods validation for macromolecules: summary report
-
Miller K.J., Bowsher R.R., Celniker A., Gibbons J., Gupta S., Lee J.W., Swanson S.J., Smith W.C., Weiner R.S. Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm. Res. 2001, 18:1373-1383.
-
(2001)
Pharm. Res.
, vol.18
, pp. 1373-1383
-
-
Miller, K.J.1
Bowsher, R.R.2
Celniker, A.3
Gibbons, J.4
Gupta, S.5
Lee, J.W.6
Swanson, S.J.7
Smith, W.C.8
Weiner, R.S.9
-
24
-
-
34247894006
-
Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples
-
Nowatzke W., Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J. 2007, 9:E117-E122.
-
(2007)
AAPS J.
, vol.9
-
-
Nowatzke, W.1
Woolf, E.2
-
25
-
-
0028057250
-
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
-
Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
-
(1994)
Blood
, vol.83
, pp. 435-445
-
-
Reff, M.E.1
Carner, K.2
Chambers, K.S.3
Chinn, P.C.4
Leonard, J.E.5
Raab, R.6
Newman, R.A.7
Hanna, N.8
Anderson, D.R.9
-
26
-
-
24044467097
-
Bioanalytical method validation for macromolecules in support of pharmacokinetic studies
-
Smolec J., DeSilva B., Smith W., Weiner R., Kelly M., Lee B., Khan M., Tacey R., Hill H., Celniker A., Shah V., Bowsher R., Mire-Sluis A., Findlay J.W., Saltarelli M., Quarmby V., Lansky D., Dillard R., Ullmann M., Keller S., Karnes H.T. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res. 2005, 22:1425-1431.
-
(2005)
Pharm. Res.
, vol.22
, pp. 1425-1431
-
-
Smolec, J.1
DeSilva, B.2
Smith, W.3
Weiner, R.4
Kelly, M.5
Lee, B.6
Khan, M.7
Tacey, R.8
Hill, H.9
Celniker, A.10
Shah, V.11
Bowsher, R.12
Mire-Sluis, A.13
Findlay, J.W.14
Saltarelli, M.15
Quarmby, V.16
Lansky, D.17
Dillard, R.18
Ullmann, M.19
Keller, S.20
Karnes, H.T.21
more..
-
29
-
-
43949156757
-
CD20: a regulator of cell-cycle progression of B lymphocytes
-
Tedder T.F., Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 1994, 15:450-454.
-
(1994)
Immunol. Today
, vol.15
, pp. 450-454
-
-
Tedder, T.F.1
Engel, P.2
|